Solutions - Page 11

Excelsior Sciences, which spun out of investment firm Deerfield Management, has roped in $95 million to scale its chemical synthesis “smart bloccs” platform, invest in its internal pipeline and forge partnerships across

Tuesday, the European Council gathered behind new regulations that seek to diversify local biopharma supply chains, support collaborative drug procurement models and devise incentives to bolster drug production in the bloc.

The manufacturing center of excellence, proposed in a recent congressional bill, would boost innovation and train workers to bolster production talent throughout the industry.

Even as moving tariff targets and a capricious market have injected uncertainty into the operations of many biopharma players this year, it’s hard to deny the effect that President Donald Trump’s trade

Microsize, a U.S.-based CDMO that specializes in particle size reduction and control technologies, has linked with Switzerland’s Schedio Group to acquire a Lonza micronization facility for an undisclosed price.

Less than a week after Novartis unveiled a plan to establish a “flagship manufacturing hub” in North Carolina that would add 700 employees to its rolls, the Swiss drugmaker says it is

Maryland is becoming the home away from home for British drugmaker AstraZeneca. On Friday, the biopharma powerhouse upped its ante in the Old Line State, saying it will invest $2 billion to

Cdymax Pharma has been slapped with a warning letter from the FDA outlining two observations against the Bangalore, India-based API maker, both linked to testing shortfalls.

With a $140 million investment, Moderna will build a new facility at its manufacturing campus in Norwood, Massachusetts. The new plant will allow the company to execute end-to-end clinical- and commercial-stage production

Antheia is teaming up with TAPI—Teva’s active pharmaceutical ingredient and contract manufacturing business—in a bid to further commercialize its pipeline of biosynthetic drug ingredients and key start materials.